NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
FebruaryTimelineMarketsDigestTalksIranFaceDiplomaticThursdayStrikesTargetsStatePredictionLaunchesMilitaryPressureNuclearIranianIsraelIssuesChinaHongParticularlyGovernment
FebruaryTimelineMarketsDigestTalksIranFaceDiplomaticThursdayStrikesTargetsStatePredictionLaunchesMilitaryPressureNuclearIranianIsraelIssuesChinaHongParticularlyGovernment
All Articles
STAT+: HHS adviser hopes prior authorization reform happens in ‘double-digit months,’ not years
STAT News
Published about 16 hours ago

STAT+: HHS adviser hopes prior authorization reform happens in ‘double-digit months,’ not years

STAT News · Feb 25, 2026 · Collected from RSS

Summary

A top federal health official said he hopes the Trump administration’s efforts to whittle down the insurance industry’s use of prior authorizations will produce results “in double-digit months” instead of…

Full Article

WASHINGTON — A top U.S. health official told a room full of doctors on Wednesday that he hopes the Trump administration’s efforts to whittle down the insurance industry’s use of prior authorizations will produce results “in double-digit months” instead of years, calling on his audience to also put pressure on their technology vendors to standardize the process. “There should be no human working on prior authorization, period,” Chris Klomp, director of the Center for Medicare, said. “We have the technology to effectuate appropriate clinical care based on your judgment, your decisions, very, very quickly, and that’s what we’re driving for.” Klomp, who now also serves as a senior counselor at the Department of Health and Human Services, overseeing the department’s day-to-day operations, made his comments at the American Medical Association’s national advocacy conference in Washington, D.C. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe


Share this story

Read Original at STAT News

Related Articles

STAT Newsabout 8 hours ago
Trump administration pauses some Medicaid funding to Minnesota, citing fraud concerns

Vice President JD Vance announced Wednesday that the Trump administration would “temporarily halt” some Medicaid funding to the state of Minnesota over fraud concerns.

STAT Newsabout 8 hours ago
STAT+: Sarepta Therapeutics CEO Doug Ingram will retire after a tumultuous decade

Sarepta's CEO will retire after a tumultuous decade in which Sarepta became a $15 billion company — and then that value collapsed.

STAT Newsabout 12 hours ago
Surgeon general nominee and senator face off over vaccines and ‘shared decision-making’

Casey Means wanted to talk about chronic disease. But Bill Cassidy wanted to hear about her views on vaccines.

STAT Newsabout 15 hours ago
STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA

Drugmakers thought they had the FDA's buy-in to approve a therapy to treat a type of cancer that can quickly turn deadly. The agency, however, rejected it.

STAT Newsabout 18 hours ago
Casey Means, a MAHA leader, makes bid to be nation’s top doctor

Casey Means, now the epitome of a “MAHA mom," invokes motherhood and “wholeness” in health in making her case to be the U.S. surgeon general.

STAT Newsabout 18 hours ago
STAT+: Novo doubles down on oral peptides

Novo slashes list prices, GSK acquires a pulmonary hypertension drug, and other biotech news